[go: up one dir, main page]

CO2017008469A2 - Anticuerpos anti-transtiretina - Google Patents

Anticuerpos anti-transtiretina

Info

Publication number
CO2017008469A2
CO2017008469A2 CONC2017/0008469A CO2017008469A CO2017008469A2 CO 2017008469 A2 CO2017008469 A2 CO 2017008469A2 CO 2017008469 A CO2017008469 A CO 2017008469A CO 2017008469 A2 CO2017008469 A2 CO 2017008469A2
Authority
CO
Colombia
Prior art keywords
ttr
antibodies
transthyretin
accumulation
amyloidosis
Prior art date
Application number
CONC2017/0008469A
Other languages
English (en)
Inventor
Tarlochan S Nijjar
Avijit Chakrabartty
Jeffrey N Higaki
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of CO2017008469A2 publication Critical patent/CO2017008469A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona anticuerpos que se enlazan específicamente a transtiretina (TTR). Los anticuerpos pueden utilizarse para el tratamiento o profilaxis de efectos de enfermedades o trastornos asociados con la acumulación de TTR o la acumulación de depósitos de TTR (por ejemplo, amiloidosis de TTR). Los anticuerpos también pueden utilizarse para diagnosticar la amiloidosis e inhibición de TTR o reducir la agregación de TTR, entre otras aplicaciones.
CONC2017/0008469A 2015-01-28 2017-08-22 Anticuerpos anti-transtiretina CO2017008469A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109001P 2015-01-28 2015-01-28
US201562266557P 2015-12-11 2015-12-11
PCT/IB2016/050414 WO2016120809A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (1)

Publication Number Publication Date
CO2017008469A2 true CO2017008469A2 (es) 2018-01-16

Family

ID=55361912

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0008469A CO2017008469A2 (es) 2015-01-28 2017-08-22 Anticuerpos anti-transtiretina

Country Status (19)

Country Link
US (1) US20160257736A1 (es)
EP (1) EP3250594B1 (es)
JP (2) JP6875280B2 (es)
KR (1) KR102619359B1 (es)
CN (1) CN107428822B (es)
AU (1) AU2016210887B2 (es)
CA (1) CA2974911A1 (es)
CO (1) CO2017008469A2 (es)
CU (1) CU24532B1 (es)
EA (1) EA036048B1 (es)
ES (1) ES2905311T3 (es)
MX (1) MX391789B (es)
MY (1) MY193674A (es)
PE (1) PE20180200A1 (es)
SA (1) SA517381991B1 (es)
SG (1) SG11201706125QA (es)
TW (2) TWI781507B (es)
WO (1) WO2016120809A1 (es)
ZA (1) ZA201705662B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI781507B (zh) * 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7076711B2 (ja) * 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
CN111315213B (zh) 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 抗甲状腺素运载蛋白抗体
WO2019071206A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited METHODS OF DETECTING TRANSTHYRETIN
CN111433223B (zh) 2017-11-29 2024-08-27 诺和诺德A/S（股份有限公司） 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
TW202525341A (zh) 2023-12-15 2025-07-01 丹麥商諾佛 儂迪克股份有限公司 穩定的液體調配物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CA2361492A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
ES2289174T3 (es) 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
DE50308030D1 (de) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
PT1820022E (pt) 2004-11-10 2009-08-05 Boehringer Ingelheim Pharma Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
ES2397274T3 (es) 2007-03-02 2013-03-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mejora de la producción de proteínas
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
EP2953970A4 (en) * 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Also Published As

Publication number Publication date
JP2021129562A (ja) 2021-09-09
AU2016210887A1 (en) 2017-08-10
BR112017016324A2 (pt) 2018-03-27
JP7219928B2 (ja) 2023-02-09
JP6875280B2 (ja) 2021-05-26
AU2016210887B2 (en) 2021-11-04
EP3250594A1 (en) 2017-12-06
US20160257736A1 (en) 2016-09-08
KR102619359B1 (ko) 2024-01-02
TW201636372A (zh) 2016-10-16
CN107428822A (zh) 2017-12-01
ZA201705662B (en) 2018-08-29
MY193674A (en) 2022-10-24
MX391789B (es) 2025-03-21
ES2905311T3 (es) 2022-04-07
JP2018509889A (ja) 2018-04-12
CA2974911A1 (en) 2016-08-04
SG11201706125QA (en) 2017-08-30
TW202118782A (zh) 2021-05-16
CN107428822B (zh) 2021-11-23
KR20170120607A (ko) 2017-10-31
EP3250594B1 (en) 2021-11-17
CU24532B1 (es) 2021-07-02
WO2016120809A1 (en) 2016-08-04
PE20180200A1 (es) 2018-01-31
EA036048B1 (ru) 2020-09-18
EA201791711A1 (ru) 2017-11-30
SA517381991B1 (ar) 2021-12-13
TWI718121B (zh) 2021-02-11
MX2017009804A (es) 2018-08-15
TWI781507B (zh) 2022-10-21
CU20170096A7 (es) 2018-03-13

Similar Documents

Publication Publication Date Title
CO2017008469A2 (es) Anticuerpos anti-transtiretina
CO2017008476A2 (es) Anticuerpos anti-transtiretina
CO2017008482A2 (es) Anticuerpos anti-transtiretina
CU20200021A7 (es) Anticuerpos anti-transtiretina
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
WO2018007923A3 (en) Anti-transthyretin antibodies
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
WO2018007924A3 (en) Anti-transthyretin antibodies
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
WO2018007922A3 (en) Anti-transthyretin antibodies
MX2016016534A (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
AR113345A1 (es) Anticuerpos anti-transtiretina
BR112017007112A2 (pt) compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
AR103549A1 (es) Anticuerpos anti-transtiretina
HK1240249A1 (en) Anti-transthyretin antibodies
AR103548A1 (es) Anticuerpos anti-transtiretina